The molecular targets of four out of nine approved ADCs are homogenously expressed within the target cancer tissues: inotuzumab ozogamicin (indicated as B cell precursor in ALL and targeting CD22) [86], gemtuzumab ozogamicin (approved for CD33-positive AML and targeting CD33) [87], brentuximab vedotin (indicated in Hodgkin’s lymphoma, ALCL, PTCL and MF and targeting CD30) [88], and polatuzumab vedotin (indicated in DLBCL and targeting CD79) [89]. The gene discussed is CD33; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.